The Clinical Use of Cisapride in Gastro-oesophageal Reflux Disease, with Particular Focus on the Long-term Treatment Aspects

Abstract

Background: The healing of oesophagitis, both symptomatic and endoscopic, can be obtained with cisapride, the results being equivalent to what has been achieved with H₂ RAs. For many patients, however, GORD is a chronic relapsing disease. Results: At least 40–50% of patients relapse within a year of initial healing. Important predictors for relapse are the severity of symptoms, the degree of mucosal damage, and the time it takes for the initial lesions to heal. Another important predictor of relapse, as shown in the cisapride maintenance studies, is the need for PPIs, probably because the most recalcitrant patients were selected for this therapy. Conclusions: Patients with mild or moderate disease should be treated with intermittent or prolonged therapy with cisapride or H₂RAs. Patients with severe disease should be given prolonged or permanent therapy with a PPI or with cisapride in combination with either an H₂RA or a PPI. For the latter group, antireflux surgery should also be considered, especially in younger patients who have a completely incompetent closing mechanism of the lower oesophageal sphincter.

Key Words:

• Cisapride
• gastro-oesophageal reflux
• long-term treatment